Memorial Sloan Kettering Cancer Center
Computational Oncology
Dr. Elsa Bernard is a computational cancer scientist with strong interest in studying myelodysplastic syndromes and other myeloid malignancies. She combines cancer genomic techniques with statistical learning to describe the molecular underpinning of the disease, integrate molecular and clinical data, and build predictive and prognostic models. She works closely with clinicians, pathologists and biologists to bring the latest genomic discovery into effective clinical decision support tools. She is part of the International Working Group for the prognosis of MDS.
Presenter of 2 Presentations
The New Molecular IPSS in Clinical Practice
Date
05/05/2023
Room
Callelongue Room
Session Type
Meet the Expert
Lecture Time
08:00 - 08:45
The New Molecular IPSS
Date
05/04/2023
Room
Auditorium
Session Type
Plenary Session
Presenter
Lecture Time
14:00 - 14:15
Abstract
Abstract Body
Despite a detailed understanding of the genes mutated in myelodysplastic syndromes (MDS), diagnostic and treatment decisions for patients with MDS rely primarily on clinical and cytogenetic variables as considered by the Revised International Prognostic Scoring System (IPSS-R). Here we describe the recently developed Molecular IPSS (IPSS-M), a clinico-genomic risk stratification system that considers clinical, cytogenetic and genetic parameters; the implementation of a web portal to facilitate its adoption, a strategy to handle missing variables, and the worldwide utilization of the web calculator as a clinical support tool.